Opill 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

When the FDA approved Opill (norgestrel 0.075 mg) for over-the-counter use in July 2023 — and it launched on retail shelves in March 2024 — the promise was expanded access to contraception for patients who face barriers to healthcare. No prescription. No office visit. No insurance required. Available at pharmacies and grocery stores nationwide.

Two years into that reality, the clinical picture is more nuanced. Opill is generally available and not in a national manufacturing shortage — but providers are regularly fielding questions from patients who can't find it locally, can't afford it out of pocket, or are unsure how to integrate it into their existing contraceptive regimen. This guide addresses the key clinical and logistical considerations for 2026.

Current Availability Status of Opill

Opill is not listed on the FDA Drug Shortage Database as of 2026. Perrigo, the manufacturer, has not reported supply disruptions. Opill is available at CVS, Walgreens, Walmart, Target, Kroger, and most major pharmacy and grocery chains, as well as online at opill.com, Amazon, and GoodRx.

However, individual store stockouts occur and are most frequently reported in:

Rural and underserved communities with fewer retail options

College towns and areas with high adolescent/young adult density

Smaller independent pharmacies that have not yet added Opill to their routine stock

From a provider counseling standpoint, it's useful to advise patients that online ordering through opill.com or major retailers is the most reliable access point.

Clinical Review: Opill Pharmacology and Appropriate Use

Opill contains norgestrel 0.075 mg — a synthetic second-generation progestin. Its primary mechanisms of action are:

Thickening of cervical mucus to impede sperm penetration (primary mechanism)

Endometrial atrophy reducing implantation likelihood

Partial ovulation suppression in some cycles (not consistent across all users)

Perfect-use effectiveness is approximately 98%; typical-use effectiveness is approximately 91–93%. The 3-hour daily timing window is critical — a dose taken more than 3 hours late requires 48 hours of backup contraception.

Appropriate Patient Selection and Contraindications

Because Opill contains no estrogen, it is an appropriate contraceptive option for patients who are contraindicated for combined hormonal contraceptives, including those with:

Migraines with aura (where estrogen is contraindicated due to stroke risk)

Uncontrolled hypertension or cardiovascular risk factors

Personal history of venous thromboembolism (VTE)

Smokers over age 35

Lactating patients (progestin-only methods are generally considered safe for breastfeeding)

Absolute contraindications include current or history of breast cancer (or other progestin-sensitive cancers), active liver disease or liver tumors, unexplained vaginal bleeding, and confirmed pregnancy. Opill should not be combined with other hormonal contraceptives.

Key Drug Interactions to Counsel Patients On

Because Opill is OTC, patients may start it without disclosing it to their prescribers. Providers should proactively ask about Opill use during medication reconciliation. Critical interactions include:

CYP3A4 inducers (major interactions): Carbamazepine, phenytoin, barbiturates, oxcarbazepine, topiramate, primidone (seizure medications); rifampin, rifabutin (TB); efavirenz (HIV); bosentan (pulmonary hypertension). These significantly reduce norgestrel serum concentrations and may cause contraceptive failure. Recommend a non-hormonal or long-acting alternative.

St. John's Wort: A moderate CYP3A4 inducer; patients taking this herbal supplement should be counseled to use backup contraception.

Ulipristal acetate (ella): Opill should not be started within 5 days of ulipristal acetate use, as it reduces the efficacy of both agents.

GLP-1 receptor agonists: Delayed gastric emptying may reduce oral contraceptive absorption. Counsel patients initiating GLP-1 therapy to use backup contraception for 4 weeks.

Insurance Coverage and Prescribing Opill for Coverage

Many patients are surprised to learn that Opill, despite being OTC, is often not covered by insurance when purchased without a prescription. The ACA contraceptive mandate applies to prescription products. However, providers can write a prescription for Opill (norgestrel 0.075 mg) — which may enable insurance coverage with a $0 copay under ACA mandates for preventive contraceptive care.

Some pharmacy benefit managers (notably certain CVS Caremark plans) now cover OTC norgestrel 0.075 mg at $0 without a prescription. HSA and FSA funds can be used to purchase Opill. Some state Medicaid programs cover Opill; coverage varies by state.

When to Recommend Prescription Alternatives Instead

Opill may not be the right choice for every patient who comes in asking about OTC birth control. Consider recommending prescription alternatives when:

The patient takes interacting medications (seizure drugs, rifampin, HIV medications) — consider IUD or Nexplanon

The patient has difficulty adhering to a strict 3-hour daily window — consider Slynd (24-hour window) or long-acting method

The patient has history of breast cancer — Opill is contraindicated; recommend non-hormonal methods (copper IUD, barrier methods)

The patient prefers long-acting contraception — recommend Mirena, Liletta, Kyleena, or Nexplanon

How medfinder Supports Your Patients' Access

Providers managing patients who need help locating medications — including Opill or prescription alternatives — can recommend medfinder for providers. medfinder calls pharmacies near the patient to check real-time stock and texts results back — eliminating the need for patients to call multiple pharmacies. This is particularly valuable for patients in rural areas or those managing multiple medications.

For a patient-facing version of this content, see our Opill availability update for patients.